Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 11/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930938 | 0.87 | BRAF (0.47) | CYP2C9CYP3A4MAPTBRAFCYP2C19 | |
| SCHEMBL1462073 | 0.87 | MAPT (0.44) | CYP2C9CYP3A4MAPTBRAFCYP2C19 | |
| SCHEMBL1437637 | 0.83 | PSIP1 (0.56) | CYP2C9CYP3A4BRAFCYP2C19ALOX5AP | |
| SCHEMBL10129554 | 0.82 | ACLY (0.44) | CYP2C9CYP3A4BRAFCYP2C19ALOX5AP | |
| SCHEMBL1818143 | 0.82 | CYP2C9 (0.68) | CYP2C9CYP3A4MAPTBRAFCYP2C19 | |
| SCHEMBL9930367 | 0.81 | CYP2C9 (0.57) | CYP2C9CYP3A4MAPTBRAFCYP2C19 | |
| SCHEMBL14964586 | 0.81 | CYP3A4 (0.47) | CYP2C9CYP3A4BRAFCYP2C19PSIP1 | |
| SCHEMBL914674 | 0.80 | CYP2C9 (0.55) | CYP2C9CYP3A4MAPTBRAFCYP2C19 | |
| SCHEMBL1437671 | 0.79 | CYP3A4 (0.68) | CYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL20408709 | 0.79 | CYP2C9 (0.57) | CYP2C9CYP3A4MAPTBRAFCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2655355-B1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20130023531-A1 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| CN-102712646-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2012-10-03 | — | — | CN | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2470538-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | CYP2C9 4366/4885CYP3A4 4045/4885MAPT 2146/4885 |
| US-20130023531-A1 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | CDK2, CDK4, CCNI | CYP2C9 2373/4885CYP3A4 1974/4885MAPT 3614/4885 |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2C9 2926/4885CYP3A4 2785/4885MAPT 1082/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2C9 2926/4885CYP3A4 2785/4885MAPT 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.